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Abstract
Background: Contrast-induced nephropathy is an important cause of acute renal failure. We
assess the efficacy of acetylcysteine for prevention of contrast-induced nephropathy among
patients undergoing intravascular angiography.
Methods: We conducted a systematic review and meta-analysis of randomized controlled trials
comparing prophylactic acetylcysteine plus hydration versus hydration alone in patients undergoing
intravascular angiography. Studies were identified by searching MEDLINE, EMBASE, and CENTRAL
databases. Our main outcome measures were the risk of contrast-induced nephropathy and the
difference in serum creatinine between acetylcysteine and control groups at 48 h.
Results: Fourteen studies involving 1261 patients were identified and included for analysis, and
findings were heterogeneous across studies. Acetylcysteine was associated with a significantly
reduced incidence of contrast-induced nephropathy in five studies, and no difference in the other
nine (with a trend toward a higher incidence in six of the latter studies). The pooled odds ratio for
contrast-induced nephropathy with acetylcysteine relative to control was 0.54 (95% CI, 0.32–0.91,
p = 0.02) and the pooled estimate of difference in 48-h serum creatinine for acetylcysteine relative
to control was -7.2 µmol/L (95% CI -19.7 to 5.3, p = 0.26). These pooled values need to be
interpreted cautiously because of the heterogeneity across studies, and due to evidence of
publication bias. Meta-regression suggested that the heterogeneity might be partially explained by
whether the angiography was performed electively or as emergency.
Conclusion: These findings indicate that published studies of acetylcysteine for prevention of
contrast-induced nephropathy yield inconsistent results. The efficacy of acetylcysteine will remain
uncertain unless a large well-designed multi-center trial is performed.
Background
Contrast-induced nephropathy is a leading cause for
acquired acute reductions in kidney function [1,2].
Despite advances in supportive therapy, the incidence of
contrast-induced nephropathy may continue to increase
significantly with the broader utilization of radiocontrast
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media for diagnostic and interventional procedures.[3]
Furthermore, contrast-induced nephropathy is associated
with a greater risk of in-hospital morbidity, mortality, pro-
longed hospitalization, increased health care costs and
potentially irreversible reduction in kidney function [4-8].
The pathophysiology of contrast-induced nephropathy
remains incompletely understood. However, current evi-
dence suggests that contrast media induce prolonged
vasoconstriction and medullary ischemia coupled with
generation of free radicals and oxidative injury to tubular
cells [9-11].
Acetylcysteine, a thiol-containing anti-oxidant, has been
hypothesized to prevent contrast-induced nephropathy.
The potential benefit of acetylcysteine is believed to be
mediated by its properties as a scavenger of free-radical
species and by increasing the synthesis of nitric oxide, a
potent vasodilator, in response to ischemic or other toxic
injury in the kidney [12]. Given the recent publication of
a series of randomized controlled trials assessing the effi-
cacy of acetylcysteine in preventing the decline in kidney
function following contrast exposure associated with
intravascular angiography, we sought to conduct a system-
atic review and meta-analysis of these trials. The specific
objectives of our meta-analysis were to assess the effect of
acetycysteine on 1) the dichotomous endpoint of con-
trast-induced nephropathy (yes/no) and 2) serum creati-
nine levels following the administration of contrast
media. We also conduct a meta-regression analysis to
determine whether particular clinical or study quality fac-
tors influence the apparent effect of acetylcysteine on risk
of contrast-induced nephropathy.
Methods
Search strategy
We identified published randomized controlled trials of
acetylcysteine for prevention of contrast-induced neph-
ropathy during intravascular angiography using both elec-
tronic and manual search strategies. We supplemented
this by scanning the reference lists of all identified articles,
reviewing selected conference proceedings, and by con-
tacting experts in the field. All languages and types of pub-
lications were considered eligible. The comprehensive
literature search was initially performed in April 2003 and
updated in June 2004 to identify any potential new stud-
ies that may have appeared.
MEDLINE (1966 through April, 2003), EMBASE (1980
through April, 2003) and CENTRAL (Cochrane Control-
led Clinical Trials Register 1996 through April, 2003)
databases were searched via OVID using an approach rec-
ommended for systematic reviews of randomized trials
[13]. PubMed was also searched [14]. We derived three
comprehensive search themes that were then combined
using the Boolean operator 'and'. The first theme used a
recommended highly sensitive randomized controlled
trial filter and systematic review filter method [15]. The
second theme, contrast-induced nephropathy, was cre-
ated by using the Boolean search term 'or' to search for the
following terms appearing as both exploded medical sub-
ject headings (MeSH) or text words: 'contrast media' or
'radiocontrast' or 'kidney failure' or 'acute renal failure' or
' chronic renal failure' or 'contrast nephropathy' or 'dialy-
sis'. The third theme, acetylcysteine, was created by a
search using an exploded MeSH heading and textword
search for: 'N-acetylcysteine' or 'NAC' or 'acetylcysteine' or
'Mucomyst'.
Study selection criteria
Two individuals (SMB and WAG) independently evalu-
ated identified articles for eligibility on the basis of four
inclusion criteria: 1) study design (randomized controlled
trials), 2) target population (patients undergoing intravas-
cular angiography), 3) intervention (trials of acetyl-
cysteine plus hydration versus control) and 4) outcome
(trials with explicit definition of contrast-induced
nephropathy).
Data extraction
Two reviewers (SMB and WAG) independently extracted
data from all primary studies fulfilling eligibility criteria.
Any discrepancies in extracted data were resolved by con-
sensus. Data extracted included identifying information,
focus of the study, details of study protocol and demo-
graphic data. The primary outcome measures were the
incidence of contrast-induced nephropathy and change in
serum creatinine. The secondary outcome measure was
requirement for renal replacement therapy. Authors of the
studies were contacted for additional information when
applicable.
Assessment of methodological quality
Two reviewers (SMB and WAG) independently assessed
methodological quality of individual studies. Any disa-
greements were resolved by consensus. Items used to
assess study quality were methods of randomization, any
blinding, use of a placebo, reporting of losses to follow-up
or missing outcome assessments, and evidence of impor-
tant baseline differences between the groups [16-18]. An
overall quality score was determined for each study as
described by Jadad et al [16].
Prior hypotheses regarding sources of heterogeneity
The presence of heterogeneity can compromise the inter-
pretation and validity of meta-analyses and can result
from significant differences in methodology, study popu-
lations, interventions, outcomes, or chance [19]. A priori
consideration of potential factors contributing to hetero-
geneity for acetylcysteine in prevention of contrast-BMC Medicine 2004, 2:38 http://www.biomedcentral.com/1741-7015/2/38
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induced nephropathy included baseline serum creatinine
levels, volume of contrast media, volume of hydration,
age, diabetes mellitus, elective or emergency procedure,
and a number of trial methodology factors.
Statistical methods
Data from all of the selected randomized controlled trials
were combined to estimate the pooled odds ratio (OR)
with 95% confidence intervals (CIs) using a random-
effects model as described by Der Simonian and Laird
[20,21]. The presence of heterogeneity across trials was
evaluated using a chi-square test for homogeneity [22].
Meta-regression was performed to analyze for potential
clinical and study quality factors that may influence treat-
ment effects. We tested for potential publication bias
using both a Begg's test for asymmetry and an Egger's test
[23,24]. All statistical analyses were performed with Stata
version 8.0 (StataCorp, College Station, TX).
Results
Identification of studies
A total of 66 unique citations were identified by our initial
search strategy (Figure 1). After the initial screen, 22 cita-
tions warranted further review. Among these, 15 citations
were excluded: 8 were clinical reviews, 3 were prospective
cohort studies, 2 were substudies of previously published
randomized controlled trials, one did not include a con-
trol group, and one did not involve intravascular angiog-
raphy. Therefore, we had identified 7 studies for
inclusion. A repeat search of the literature conducted in
June 2004 yielded seven additional eligible studies. Over-
all, 14 studies thus fulfilled our inclusion criteria [25-38].
All of these citations were identified by the electronic
search strategy and are published in peer-reviewed jour-
nals [39].
Study characteristics
All the randomized controlled trials were published in the
years 2002 through 2004. Tables 1 and 2 present the char-
acteristics of the 14 randomized controlled trials. A total
of 1261 patients were studied in these 14 randomized
controlled trials, among whom 631 received acetyl-
cysteine and 630 were in control groups. There were 563
(44.6%) patients with diabetes mellitus, of whom 284
were assigned to receive acetylcysteine and 279 were
assigned to a control group. The dosing and schedule of
administration of acetylcysteine was variable across stud-
ies; however, in the majority of studies, acetylcysteine was
initiated 12–24 h prior to angiography. In two trials, large
doses of acetylcysteine were administered immediately
prior to (within 1 h) and shortly following (within 3–4 h)
angiography [26,29]. All patients were administered a
hydration protocol around their procedure and all
received low or iso-osmolar non-ionic contrast media.
The definition of contrast-induced nephropathy was vari-
able across studies. Four studies defined contrast-induced
nephropathy as a > 44.2 µmol/L increase in serum creati-
nine from baseline [25,29,32,37], four used a > 25%
increase in serum creatinine from baseline [26,30,33,35],
four used either a > 44.2 µmol/L or a > 25% increase in
serum creatinine from baseline [28,31,34,36], one used
either a > 44.2 µmol/L or a > 33% increase in serum creat-
inine from baseline[38] and one study combined either a
> 25% increase in serum creatinine from baseline or dial-
ysis [27]. Generally, the time for ascertaining contrast-
induced nephropathy for all studies was 48 h after the
exposure to contrast media, with the exception of four
studies, where presence or absence of contrast-induced
nephropathy was determined at 24, 72 and 96 h
[26,30,34,35].
Meta-analysis of incidence of contrast-induced 
nephropathy
The reported incidence of contrast-induced nephropathy
was variable across studies. Table 3 and Figure 2 present
information on the incidence of contrast-induced neph-
ropathy for all studies. Five studies provided evidence of a
risk reduction for development of contrast-induced neph-
ropathy with acetylcysteine [26,28,33,35,37], whereas
nine studies reported no evidence of benefit [25,27,29-
32,34,36,38]. Furthermore, six of the latter studies yielded
an odds ratio > 1.0, suggesting a trend towards an
increased risk of contrast-induced nephropathy
[25,29,31,32,36,38]. The overall pooled odds ratio for
development of contrast-induced nephropathy using a
random-effects model was 0.54 (95% CI, 0.32–0.91, p =
0.022), suggesting a significant reduction in CIN with ace-
tylcysteine (Figure 2). However, this pooled odds ratio
should be interpreted with caution because the analysis
comparing the occurrence of contrast-induced nephropa-
thy across all studies revealed significant heterogeneity
(chi-square = 23.96, p = 0.032). In total, six patients
required dialysis, among whom two received acetyl-
cysteine and two were in control groups. Group assign-
ment was not reported for the other two patients who
required dialysis.
Meta-analysis of change in serum creatinine with 
acetylcysteine
Table 3 shows a summary of the changes in serum creati-
nine across studies. The pooled estimate (using a random
effects model) for the difference in 48 h serum creatinine
between the acetylcysteine and control groups was -7.2
µmol/L (95% CI -19.7 to 5.3, p = 0.26) based on data
available from eight studies [25,27,28,31,32,35,37,38].
This suggests no significant absolute change in serum cre-
atinine with the administration of acetylcysteine (Figure
3). Again, this pooled estimate requires cautious interpre-
tation owing to the availability of data from only eightBMC Medicine 2004, 2:38 http://www.biomedcentral.com/1741-7015/2/38
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Flow diagram of study selection process Figure 1
Flow diagram of study selection process.
14 Randomized controlled trials included in final analysis
7 Additional randomized controlled trials included from
follow-up verification search
7 Randomized controlled trials initially included
15 Articles Excluded: 8  Reviews
3 Prospective cohort studies 
2 Substudies of RCTs
   1  No control group
   1  Not angiography
22 Potentially relevant citations identified
for further review
66 Citations screenedBMC Medicine 2004, 2:38 http://www.biomedcentral.com/1741-7015/2/38
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Table 1: Characteristics of studies reporting on the use of acetylcysteine for prevention of contrast-induced nephropathy.
First Author Patients Diabetes Elective 
Procedure
Primary 
Outcome
Acetylcysteine 
Protocol*
Hydration 
Protocol
Contrast 
Media
Contrast Media 
Volume (mL)**
NAC Control
Allaqaband, 
200225
85 41 (48%) Unclear > 44.2 µmol/L 
increase SCr 
at 48 hrs
600 mg PO bid 
pre/post
0.45%NS 1 mL/
kg/hr 12 hr pre/
post
Ioversol or 
Iodixanol
121.6 122
Baker, 
200326
80 34 (43%) Unclear > 25% 
increase SCr 
at 48 or 96 
hrs
150 mg/kg IV 30 
min pre & 50 mg/
kg IV infusion 4 
hrs post
Control 0.9%NS 
1 mL/kg/hr 12 hr 
pre/post
Iodixanol 238 222
Briguori, 
200227
183 69 (38%) Yes > 25% 
increase SCr 
at 48 hrs or 
dialysis
600 mg PO bid 
pre/post
0.45%NS 1 mL/
kg/hr 12 hr pre/
post
Iopromide 194 200
Diaz-
Sandoval, 
200228
54 21 (39%) Yes > 44.2 µmol/L 
or 25% SCr 
increase at 48 
hrs
600 mg PO bid 
pre/post
0.45%NS 1 mL/
kg/hr 2–12 hr pre 
& 12 hr post
Ioxilan 179 189
Durham, 
200229
79 38 (48%) No > 44.2 µmol/L 
increase SCr 
at 48 hrs
1200 mg PO 1 hr 
pre and 3 hr post
0.45%NS 1 mL/
kg/hr 12 hr pre/
post
Iohexol 77.4 84.7
Efrati, 
200330
49 26 (53%) Yes >25% increase 
SCr at 24 or 
96 hrs
1000 mg PO bid 
day pre/post
0.45%NS 1 mL/
kg/hr 12 hr pre/
12 post
Iopromide 142 138
Fung, 200431 91 48 (53%) Yes >44.2 µmol/L 
or 25% 
decrease in 
GFR
400 mg PO tid 
day prior/post
0.9%NS 100 ml/
hr 12 hr pre/12 
post
Iopromide 135.8 121
Goldenberg, 
200432
80 43 (54%) No >44.2 µmol/L 600 mg PO bid 
day prior/post
0.45%NS 1 mL/
kg/hr 12 hr pre/
12 post
Iopamidol 111 138
Kay, 200333 200 75 (38%) Yes > 25% 
increase SCr 
at 48 hrs
600 mg PO bid × 
4 (3 pre)
0.9%NS 1 mL/kg/
hr 12 hr pre & 6 
hr post
Iopamidol 130 120
Kefer, 
200334
104 13 (13%) Unclear > 44.2 µmol/L 
increase SCr 
at 24 hrs
1200 mg IV 12 hr 
pre & 
immediately post
D5W 20 mL/hr 
12 hr pre & 24 hr 
post
Iopromide 
or Iohexol
NR NR
MacNeill, 
200335
43 20 (46%) Yes > 25% 
increase SCr 
at 72 hrs
600 mg PO × 5 
(2 pre)
Inpatient: 
0.45%NS 1 mL/
kg/hr 12 hr pre 
Outpatient: 
0.45%NS 2 mL/
kg/hr 4 hr pre & 
both 12 hr post
Iopromide 
or Ioxilan
103 116
Oldemeyer, 
200336
96 43 (45%) Yes > 44.2 µmol/L 
or 25% SCr 
increase at 48 
hrs
1500 mg bid × 4 
(1 pre)
0.45%NS 1 mL/
kg/hr 12 hr pre/
post
Iopamidol 134 127
Shyu, 200237 121 77 (64%) Yes > 44.2 µmol/L 
increase SCr 
at 48 hrs
400 mg PO bid 
pre/post
0.45%NS 1 mL/
kg/hr 12 hr pre/
post
Iopamidol 119 115
Vallero, 
200238
100 23 (23%) Unclear > 44.2 µmol/L 
or 33% 
increase SCr 
at 48 hrs
600 mg PO bid 
pre/post
0.45%NS 1 mL/
kg/hr 1–2 hr pre 
& 24 hr post
Iodixanol 187.8 219
Legend: NR = not recorded or available; NAC=acetycysteine; SCr=serum creatinine (for conversion to mg/dL divide by 88.4). *NAC administered 
with hydration protocol. **Data presented as means.BMC Medicine 2004, 2:38 http://www.biomedcentral.com/1741-7015/2/38
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studies and to the presence of significant heterogeneity
across studies (Q = 50.9, p < 0.0005). The change in serum
creatinine at 96 h was assessed in two studies as a primary
outcome [26,30]. The pooled estimate for the difference
in 96-h serum creatinine for these two studies was simi-
larly non-significant [-1.8 µmol/L (95% CI -8.9 to 5.2, p =
0.61)].
Meta-regression
Meta-regression was performed to assess a number of clin-
ical and study quality factors that may have led to hetero-
Table 2: Summary of quality indicators for studies of acetylcysteine for prevention of contrast-induced nephropathy.
First Author Jadad 
score
Inclusion/
exclusion 
criteria 
specified
Randomi-
zation 
process 
described
Use of any 
blinding
Placebo-
controlled
Reported 
loss to 
follow-up
Intention-
to treat 
analysis
Potential 
important 
baseline 
differences
Power 
calculation
Allaqaband25 3 yes/no yes yes yes no no no yes
Baker26 2 yes/yes yes no yes no yes no yes
Briguori27 1 yes/no yes no no no unclear yes no
Diaz-Sandoval28 4 yes/yes yes yes no yes unclear yes no
Durham29 5 yes/yes yes yes yes yes unclear no yes
Efrati30 4 yes/yes no yes yes yes unclear no no
Fung31 4 yes/yes yes no no no yes no yes
Goldenberg32 5 yes/yes yes yes yes no unclear no yes
Kay33 5 yes/yes yes yes yes yes yes no yes
Kefer34 4 yes/yes yes yes yes yes unclear yes no
MacNeill35 4 yes/yes yes no yes no unclear no yes
Oldemeyer36 4 yes/yes yes yes no yes unclear no no
Shyu37 3 yes/yes yes yes no yes unclear no no
Vallero38 2 yes/yes yes no no no unclear yes no
Legend: NR = not recorded or available; Jadad score range 0–5.
Table 3: Summary of outcomes of studies of acetylcysteine for prevention of contrast-induced nephropathy.
First Author Contrast-induced 
nephropathy*
Acetylcysteine Serum 
Creatinine (µmol/L)
Control Serum 
Creatinine (µmol/L)
Dialysis (N)
Acetylcysteine Control Baseline Second 
SCr
Baseline Second 
SCr
NAC Control
Allaqaband25 8/45 (18%) 6/40 (15%) 194.5 196.3 179.5 179.5 2 0
Baker26 2/41 (5%) 8/39 (21%) 163.6 156.5 154.7 159.1 0 0
Briguori27 6/92 (7%) 10/91 (11%) 134.4 130.8 136.1 135.3 0 1
Diaz-Sandoval28 2/25 (8%) 13/29 (45%) 146.7 135.5 137.9 166.2 0 0
Durham29 10/38 (26%) 9/41 (22%) 194.5 NR 203.3 NR NR NR
Efrati30 0/24 (0%) 2/25 (8%) 135.3 143.2 131.7 143.2 0 0
Fung31 8/46 (17%) 6/45 (13%) 200.7 216.6 209.5 212.2 NR NR
Goldenberg32 4/41 (10%) 3/39 (8%) 176.8 176.8 168.0 165.3 0 0
Kay33 4/102 (4%) 12/98 (12%) 119.3 107.8 120.2 122.0 0 0
Kefer34 2/53 (8%) 3/51 (6%) 91.9 91.1 102.5 93.7 0 0
MacNeill35 1/21 (5%) 7/22 (32%) 167.1 168.0 168.0 210.4 NR NR
Oldemeyer36 4/49 (8%) 3/47 (6%) 144.1 NR 146.7 NR 0 0
Shyu37 2/60 (3%) 15/61 (25%) 247.5 221.0 247.5 274.0 0 1
Vallero38 4/47 (9%) 4/53 (8%) 87.5 93.7 84 86.6 NR NR
Legend: SCr = serum creatinine (for conversion to mg/dL divide by 88.4); NR = not recorded or available. *Values are numbers of patients with 
contrast-induced nephropathy/total number of patients in treatment group (%).BMC Medicine 2004, 2:38 http://www.biomedcentral.com/1741-7015/2/38
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geneity across studies. Interestingly, these analyses suggest
that the heterogeneity may be partially explained by
whether the angiography procedures were performed elec-
tively or as emergency, because studies where all enrolled
patients were undergoing elective procedures had signifi-
cantly lower odds ratios than did studies where emergency
cases were included (coefficient for "elective-only" stud-
ies, -0.6, 95% CI, -1.24 to 0.03, p = 0.06).
Other meta-regression analyses demonstrated that the
heterogeneity could not be accounted for by differences in
patient age (coefficient -0.04, 95% CI, -0.2 to 0.1, p = 0.6),
baseline serum creatinine (coefficient -0.001, 95% CI, -
0.01 to 0.01, p = 0.9), volume of contrast media (- 0.006,
95% CI, -0.02 to 0.07, p = 0.4) or diabetes mellitus
(coefficient -0.01, 95% CI, -0.03 to 0.02, p = 0.6). Like-
wise, heterogeneity was not accounted for by differences
in study quality including use of blinding (coefficient -
0.6, 95% CI, -1.7 to 0.5, p = 0.3), concealment of rand-
omization (coefficient -0.8, 95% CI, -3.8 to 2.1, p = 0.6),
use of placebo (coefficient -0.6, 95% CI, -1.7 to 0.5, p =
0.30, consecutive patient enrollment (coefficient 0.5, 95%
CI, -1.5 to 2.4, p = 0.6) or overall Jadad score (coefficient
0.05, 95% CI, -0.4 to 0.5, p = 0.8).
There was some evidence to suggest possible publication
bias according to Begg's test (p = 0.03, with continuity cor-
rection) and a trend with Egger's test (coefficient -3.03,
95% CI, -6.71 to 0.65, p = 0.09). Figure 4 demonstrates
this graphically, as there is asymmetry in the funnel plot
with a predominance of studies with large standard errors
(i.e., usually small studies) showing benefit associated
with acetylcysteine and a paucity of small negative studies.
Discussion
Our meta-analysis of 14 peer-reviewed studies of patients
undergoing intravascular angiography may lead some to
conclude that the administration of acetylcysteine causes
a reduced incidence of contrast-induced nephropathy.
However, such a conclusion may be premature based on
Forest plot of odds ratios for development of contrast-induced nephropathy from 14 trials Figure 2
Forest plot of odds ratios for development of contrast-induced nephropathy from 14 trials.
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 1.23 (0.39,3.89)  Allaqaband   9.2
 0.20 (0.04,1.00)  Baker   6.4
 0.57 (0.20,1.63)  Briguori   9.9
 0.11 (0.02,0.54)  Diaz-Sandoval   6.4
 1.27 (0.45,3.57)  Durham  10.1
 0.19 (0.01,4.21)  Efrati   2.5
 1.37 (0.43,4.32)  Fung   9.2
 1.30 (0.27,6.21)  Goldenberg   6.7
 0.29 (0.09,0.94)  Kay   9.1
 0.63 (0.10,3.92)  Kefer   5.5
 0.11 (0.01,0.97)  MacNeill   4.2
 1.30 (0.28,6.16)  Oldemeyer   6.7
 0.11 (0.02,0.49)  Shyu   6.9
 1.14 (0.27,4.83)  Vallero   7.3
 0.54 (0.32,0.91)  Overall (95% CI)BMC Medicine 2004, 2:38 http://www.biomedcentral.com/1741-7015/2/38
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data published to date because our systematic review
reveals considerable heterogeneity of findings across tri-
als. Furthermore, our meta-analysis of post-treatment cre-
atinine values does not reveal any truly meaningful
difference in serum creatinine levels at 48 h between the
acetylcysteine and control groups. Finally, insufficient
data are available to allow inferences to be drawn about
the efficacy of acetylcysteine on clinically meaningful end-
points such as dialysis, length of hospitalization or
mortality.
This meta-analysis has several features that distinguish it
from a similar meta-analysis by Birck et al that recently
received considerable attention, and that rather firmly
concluded that acetylcysteine is beneficial [40]. First,
though our meta-analysis yielded a similar overall
reduction in the incidence of contrast-induced nephropa-
thy, we have included seven additional studies. Second,
we have focused primarily on patients undergoing intra-
vascular angiography. Third, we have used the pooled
odds ratio across studies as a summary statistic because of
its theoretical advantage to the use of relative risks in
meta-analysis [21]. Fourth, we have included an analysis
of differences in serum creatinine to complement the
dichotomous endpoint of contrast-induced nephropathy.
Fifth, we pointedly draw attention to the fact that there is
some evidence to suggest publication bias, or at the very
least funnel plot asymmetry. And finally, perhaps most
importantly, we have explored the heterogeneity in results
across studies in much greater detail than do Birck et al,
and more directly address the relevance of this heteroge-
neity in the overall interpretation of study results. Two
other meta-analyses have also recently been published,
and similarly concluded that acetylcysteine is beneficial;
however, these studies also failed to adequately address
the issue of the considerable heterogeneity across studies
[41,42]. Collectively, these three previously published
meta-analyses unfortunately send a misleading bottom-
line message to the medical community – that the evi-
dence in favor of acetylcysteine is firm [43]. Many will cor-
Forest plot of differences in serum creatinine between acetylcysteine and control at 48 h after contrast media administration  from eight trials Figure 3
Forest plot of differences in serum creatinine between acetylcysteine and control at 48 h after contrast media administration 
from eight trials.
Difference in Serum Creatinine at 48 Hours
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respondingly infer from these three 'positive' meta-
analyses that there is no longer a need for primary
research into the efficacy of acetylcysteine. Our global
conclusion, meanwhile, is rather different, in that we
more cautiously conclude that further data may be needed
before a firm conclusion can be made regarding the effi-
cacy of acetylcysteine. Two other very recent meta-analy-
ses [44,45] make a similar conclusion to ours, though
those meta-analyses do not include as many peer-
reviewed and published studies as does our updated sys-
tematic review.
The presence of heterogeneity and/or publication bias can
compromise the interpretation of meta-analyses and
result in erroneous and potentially misleading conclu-
sions [19,43]. A striking example of early meta-analysis
producing misleading results is that of intravenous mag-
nesium in the treatment of acute myocardial infarction.
The results of two meta-analyses of several small clinical
trials on this treatment suggested a reduction in arrhyth-
mias and mortality [46,47]. Furthermore, an argument
was made at the time for the use of magnesium therapy
because of ease of use, favorable side effect profile and low
cost [47,48]. However, the subsequent publication of
ISIS-4, a large multi-center trial involving over 58,000
patients, showed not only the absence of significant
reduction in arrhythmias or mortality with magnesium,
but in fact a trend towards an increased risk of heart fail-
ure [49,50], results that have since been further validated
by publication of the MAGIC trial [51]. The early meta-
analyses on intravenous magnesium were perhaps influ-
Evidence of publication bias by Funnel plot Figure 4
Evidence of publication bias by Funnel plot. Funnel plot asymmetry is demonstrated by evidence of a cluster of small studies 
with low-protective odds ratio and the paucity of small negative studies in the lower right of the funnel plot.
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enced by publication bias and the combination of data
from several small randomized controlled trials [52].
There are many parallels between the intravenous magne-
sium story and our meta-analysis findings for
acetylcysteine. The marked heterogeneity of findings
across studies, and the finding of funnel plot asymmetry
(indicating possible publication bias), ought to be viewed
as strong cautionary points against making firm conclu-
sions about the efficacy of acetylcysteine. And while it is
true that acetylcysteine is inexpensive, easy to use and has
a favorable side-effect profile, it is probably premature to
conclude scientifically that it is definitely efficacious based
on data published to date. Our firm conclusion based on
this meta-analysis of published trails is that although the
data seem quite promising, the efficacy of acetylcysteine
has not been definitively proven.
To isolate potential sources of heterogeneity we per-
formed a meta-regression analysis exploring several clini-
cal and study quality factors. There was no evidence of
association between effect size and baseline serum creati-
nine, volume of contrast media, or diabetes mellitus, all
independently identified risk factors for development of
contrast-induced nephropathy [8,53]. However, whether
the angiographic procedure was performed electively or as
emergency showed a significant relation with the size of
the acetylcysteine effect. The need to perform emergency
cardiac angiography is common in patients presenting
with suspected acute coronary syndromes. Patients under-
going emergency coronary angiography have been shown
to have increased mortality and poor long-term survival,
independent of the development of contrast-induced
nephropathy [6,54].
Funnel plot asymmetry is often interpreted to indicate
publication bias. However, it is important to consider that
this asymmetry may also be due to other sources of bias
that deserve further examination. In particular, funda-
mental disparities in study design, inconsistencies in
methodological quality and differences in the definition
of primary outcomes may have contributed to funnel plot
asymmetry. Our meta-regression analysis explored the
potential role of several study quality factors, and none
were identified as statistically significant predictors of
apparent acetylcysteine efficacy across trials. Nonetheless,
it is quite possible that other unmeasured study quality
factors may have contributed to biased results and accom-
panying funnel plot asymmetry.
Contrast-induced nephropathy continues to be an active
subject matter for clinical investigation [55,56]. A defini-
tive randomized clinical trial comparing fenoldopam, a
selective type 1 dopamine receptor agonist, with placebo
recently demonstrated no significant difference in the
incidence of contrast-induced nephropathy or any sec-
ondary outcomes including 30 day mortality, need for
dialysis, or re-hospitalization rates [56]. Another, recent
randomized trial of 192 patients undergoing intravascular
angiography compared prophylactic acetylcysteine with
fenoldopam [57]. The results demonstrated a 9.6% abso-
lute risk reduction in patients randomized to acetyl-
cysteine (4.1% vs 13.7%, respectively). Although the
authors conclude that acetylcysteine is superior to
fenoldopam for prevention of contrast-induced nephrop-
athy, there was notably no significant difference in serum
creatinine at 48 h. Of interest, in subgroup analysis, the
authors speculate that patients with low ejection fractions
(<40%) may attain additional benefit with acetylcysteine.
Conclusion
All of the above leads us to conclude that while acetyl-
cysteine appears to be safe and inexpensive, its efficacy for
the prevention of contrast-induced nephropathy remains
unproven. The results of the trials that we reviewed to date
should be viewed as early promising evidence of benefit,
and suggest that it is now perhaps reasonable to use ace-
tylcysteine in routine care because of its relative ease of
use and safety. However, its true efficacy will remain
uncertain unless a definitive well-designed multi-center
trial is performed. Such a clinical trial will be most rele-
vant if it addresses a priori clinically meaningful end-
points of renal insufficiency, rather than surrogate
endpoints based on changes in creatinine levels alone,
and further considers stratification on hypothesized
important subgroups that may benefit such as those with
a low ejection fraction [58].
Competing interests
The authors declare that they have no competing interests.
Authors' Contributions
SMB developed the study protocol, conducted literature
search, screened articles for eligibility, extracted data, ana-
lyzed data, interpreted results, wrote and revised the man-
uscript. WAG contributed to protocol development,
screened articles for eligibility, extracted data, analyzed
data, interpreted results, and provided critique of succes-
sive drafts of the manuscript. Both authors read and
approved the final manuscript.
Acknowledgements
Dr. Ghali is supported by a Government of Canada Research Chair in 
Health Services Research, and by a Health Scholar Award from the Alberta 
Heritage Foundation for Medical Research.
References
1. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT: Hospital-
acquired renal insufficiency: A prospective study.  American
Journal of Medicine 1983, 74:243-248.BMC Medicine 2004, 2:38 http://www.biomedcentral.com/1741-7015/2/38
Page 11 of 12
(page number not for citation purposes)
2. Shusterman N, Strom B, Murray T: Risk factors and outcome of
hospital-acquired acute renal failure.  American Journal of
Medicine 1987, 83:65-71.
3. Murphy SW, Barrett BJ, Parfrey PS: Contrast nephropathy. Journal
of the American Society of Nephrology 2000, 11:177-182.
4. Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure
on mortality. JAMA 1996, 275:1489-1494.
5. Powe N, Moore R, Steinberg E: Adverse reactions to contrast
media: Factors that determine the cost of treatment. AJR
1993, 161:1089-1095.
6. Gruberg L, Mintz GS, Mehran R, Dangas G, Lansky AJ, Kent KM,
Pichard A, Satler LF, Leon MB: The prognostic implications of
further renal function deterioration within 48 h of interven-
tional coronary procedures in patients with pre-existent
chronic renal insufficiency.  Journal of the American College of
Cardiology 2000, 36:1542-1548.
7. Davidson C, Hlatky M, Morris K: Cardiovascular and renal toxic-
ity of a nonionic radiocontrast agent after cardiac
catheterization. Annals of Internal Medicine 1989, 110:119.
8. Rich MW, Crecelius CA: Incidence, risk factors, and clinical
course of acute renal insufficiency after cardiac catheteriza-
tion in patients 70 years of age or older. Archives of Internal
Medicine 1990, 150:1237-1242.
9. Bakris GZ, Lass N, Gager A: Radiocontrast medium-induced
declines in renal function: A role for oxygen free radicals. Am
J Physiol 1990, 258:F115-F120.
10. Bakris G, Lass N, Glock D: Renal hemodynamics in radiocon-
trast medium-induced renal dysfunction.  Kidney International
1999, 56:206-210.
11. Heyman S, Reichman J, Brezis M: Pathophysiology of radiocon-
trast nephropathy: a role for medullary hypoxia. Invest Radiol
1999, 34:685-691.
12. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R: N-
acetyl cysteine ameliorates ischemic renal failure. Am J Physiol
1997, 272:F292-F298.
13. Lefebvre C, Clarke M: Identifying randomized trials. In Systematic
Reviews in Health Care Second edition. Edited by: Egger M, Smith G,
Altman D. London: BMJ Publications; 2001:69-86. 
14. Robinson K, Hinegardner P, Lansing P: Development of an opti-
mal search strategy for the retrieval of controlled trials using
Pubmed. In Proc 6th Int Cochrane Collouium 1998. poster B13
15. Dickersin K, Scherer R, Lefebvre C: Identifying relevant studies
for systematic reviews. BMJ 1994, 309:1286-1291.
16. Jadad A, Moore R, Carrol D, Jenkinson C, Reynolds J, Gavaghan D,
McQuay H: Assessing the quality of reports of randomized
clinical trials: Is blinding necessary?  Control Clin Trials 1996,
17:1-12.
17. Juni P, Altman D, Egger M: Assessing the quality of randomised
controlled trials. In: Systematic Reviews in Health Care Second edi-
tion. Edited by: Egger M, Smith G, Altman D. London: BMJ Publishing;
2001:87-108. 
18. Shea B, Dube C, Moher D: Assessing the quality of reports of
systematic reviews: the QUOROM statement compared to
other tools. In: Systematic Reviews in Health Care Second edition.
Edited by: Egger M, Smith G, Altman D. London: BMJ Publishing;
2001:122-139. 
19. Thompson S: Why sources of heterogeneity in meta-analysis
should be investigated. BMJ 1994, 309:1351-1355.
20. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control
Clin Trials 1986, 7:177-188.
21. Senn S, Walter S, Olkin I: Odds ratios revisited. Evidence-Based
Med 1998, 3:71.
22. Thompson S, Sharp S: Explaining heterogeneity in meta-analy-
sis: a comparison of methods. Stat Med 1999, 18:2693-2708.
23. Dear K, Begg C: An approach to assessing publication bias
prior to performing a meta-analysis. Stat Sci 1992, 7:237-245.
24. Egger M, Davey S, Schneider M, Minder C: Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997, 315:629-634.
25. Allaqaband S, Tumuluri R, Malik A: Prospective randomized
study of N-acetylcysteine, fenoldopam, and saline for pre-
vention of radiocontrast-induced nephropathy. Catheter Cardi-
ovasc Interv 2002, 57:279-283.
26. Baker C, Wragg A, Kuna S, DePalma R, Baker L: A rapid protocol
for the prevention of contrast-inducted renal dysfunction:
The RAPPID Study. Journal of the American College of Cardiology
2003, 41:2114-2118.
27. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B: Acetylcysteine
and contrast agent-associated nephrotoxicity.  Journal of the
American College of Cardiology 2002, 40:298-303.
28. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to
prevent angiography-related renal tissue injury (The APART
Trial). American Journal of Cardiology 2002, 89:356-358.
29. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M: A rand-
omized controlled trial of N-acetylcysteine to prevent con-
trast nephropathy in cardiac angiography. Kidney International
2002, 62:2202-2207.
30. Efrati S, Dishy V, Averbukh M, Blatt A, Krakover R, Weisgarten J,
Morrow J, Stein M, Golik A: The effect of N-acetylcysteine on
renal function, nitric oxide, and oxidative stress after
angiography. Kidney International 2003, 64:2182-2187.
31. Fung J, Szeto C, Chan W, Kum L, Chan A, Wong J, Wu E, Yip G, Chan
J, Yu C, Woo K, Sanderson J: Effect of N-acetylcysteine for pre-
vention of contrast nephropathy in patients with moderate
to severe renal insufficiency: a randomized trial. American Jour-
nal of Kidney Diseases 2004, 43:801-808.
32. Goldenberg I, Schechter M, Matetzki S, Jonas M, Adam M, Pres H,
Elian D, Agranat O, Schwammenthal E, Guetta V: Oral acetyl-
cysteine as an adjunct to saline hydration for prevention of
contrast-induced nephropathy following coronary
angiography. Eur Heart J 2004, 25:212-218.
33. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A: Acetyl-
cysteine for prevention of acute deterioration of renal func-
tion following elective coronary angiography and
intervention: a randomized controlled trial.  JAMA 2003,
289:553-558.
34. Kefer J, Hanet C, Boitte S, Wilmotte L, De Kock M: Acetylcysteine,
coronary procedure and prevention of contrast-induced
worsening of renal function: which benefit for which
patients? Acta Cardiol 2003, 58:555-560.
35. MacNeill B, Harding S, Bazari H, Patton K, Colon-Hernadez P, de
Joseph D, Jang I: Prophylaxis of contrast-induced nephropathy
in patients undergoing coronary angiography. Catheter Cardio-
vasc Interv 2003, 60:458-461.
36. Oldemeyer JB, Biddle P, Wurdeman R, Mooss A, Cichowski E, Hille-
man D: Acetylcysteine in the prevention of contrast-induced
nephropathy after coronary angiography.  Am J Heart 2003,
146:e23.
37. Shyu K-G, Cheng J-J, Kuan P: Acetylcysteine protects against
acute renal damage in patients with abnormal renal function
undergoing a coronary procedure. Journal of the American College
of Cardiology 2002, 40:1383-1388.
38. Vallero A, Cesano G, Pozzato M, Garbo R, Minelli M, Quarello F, For-
mica M: Contrast nephropathy in cardiac procedures: No
advantages with prophylactic use of N-acetylcysteine
(NAC). Giornale Italiano di Nefrologia 2002, 19:529-533.
39. Cook D, Guyatt G, Ryan G, Clifton J, Buckingham L, Willan A, McIlroy
W, Oxman A: Should unpublished data be included in meta-
analyses? Current convictions and controversies. JAMA 1993,
269:2749-2753.
40. Birck R, Krzossok S, Makowetz F, Schnulle P, van der Woude F, Braun
C: Acetylcysteine for prevention of contrast nephropathy:
meta-analysis. Lancet 2003, 362:598-603.
41. Isenbarger D, Kent S, O'Malley P: Meta-analysis of randomized
clinical trials on the usefulness of acetycysteine for preven-
tion of contrast nephropathy. Am J Card 2003, 92:1454-1458.
42. Alonso A, Lau J, Jaber B, Weintraub A, Sarnak M: Prevention of
radiocontrast nephropathy with N-acetylcysteine in patients
with chronic kidney disease: a meta-analysis of randomized,
controlled trials. American Journal of Kidney Diseases 2004, 43:1-9.
43. Faddy S: Significant statistical heterogeneity in a meta-analy-
sis of the usefulness of acetylcysteine for prevention of con-
trast nephropathy. Am J Cardiol 2004, 94:414.
44. Pannu N, Manns B, Lee H, Tonelli M: Systematic review of the
impact of N-acetylcysteine on contrast nephropathy. Kidney
International 2004, 65:1366-1374.
45. Kshirsagar A, Poole C, Mottl A, Shoham D, Francechini N, Tudor G,
Agrawal M: N-acetylcysteine for the prevention of radiocon-
trast induced nephropathy: A meta-analysis of prospective
controlled trials. Journal of the American Society of Nephrology 2004,
15:761-769.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medicine 2004, 2:38 http://www.biomedcentral.com/1741-7015/2/38
Page 12 of 12
(page number not for citation purposes)
46. Teo KK, Yusuf S, Collins R, Held PH, Peto R: Effects of intravenous
magnesium in suspected acute myocardial infarction: over-
view of randomized trials. BMJ 1991, 303:1499-1503.
47. Horner S: Efficacy of intravenous magnesium in acute myo-
cardial infarction in reducing arrhythmias and mortality:
Meta-analysis of magnesium in acute myocardial infarction.
Circulation 1992, 86:774-779.
48. Yusuf S, Koon T, Woods K: Intravenous magnesium in acute
myocardial infarction. An effective, safe, simple, and inex-
pensive intervention. Circulation 1993, 87:2043-2046.
49. Group I-FISoISC: ISIS-4: A randomized factorial trial assessing
early oral captopril, oral mononitrate, and intravenous mag-
nesium sulphate in 58 050 patients with suspected acute
myocardial infarction. Lancet 1995, 345:669-685.
50. Baxter G, Sumeray M, Walker J: Infarct size and magnesium:
insights into LIMIT-2 and ISI-4 from experimental studies.
Lancet 1996, 348:1424-1426.
51. Investigators TMiCMT: Early administration of intravenous
magnesium to high-risk patients with acute myocardial inf-
arction in the Magnesium in Coronaries (MAGIC) Trial: a
randomized controlled trial. Lancet 2002, 360:1189-1196.
52. Egger M, Davey Smith G: Misleading meta-analysis. BMJ 1995,
310:352-354.
53. Guitterez N, Diaz A, Timmis G, O'Neill WW, Stevens MA, Sandberg
K, McCullough PA: Determinants of serum creatinine trajec-
tory in acute contrast nephropathy.  J Interv Cardiol 2002,
15:349-354.
54. Hemmelgarn BR, Ghali WA, Quan H, Brant R, Norris CM: Poor
long-term survival after coronary angiography in patients
with renal insufficiency. American Journal of Kidney Diseases 2001,
37:64-72.
55. Merten G, Burgess W, Gray L, Holleman J, Roush T, Kowalchuk G,
Bersin R, Moore A, Simonton C, Rittase R, Norton H, Kennedy T:
Prevention of contrast-induced nephropathy with sodium
bicarbonate. JAMA 2004, 291:2328-2334.
56. Stone G, Mc Cullough P, Tumlin J, Lepor N, Madyoon H, Murray P,
Wang A, Chu A, Schaer G, Stevens M, Wilensky R, O'Neill W:
Fenoldopam mesylate for the prevention of contrast-
induced nephropathy: A randomized controlled trial. JAMA
2003, 290:2284-2291.
57. Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri
P, Elia PP, Golia B, Lepore S, Riviezzo G, Scarpato P, Librera M, Focac-
cio A, Ricciardelli B: N-acetylcysteine versus fenoldopam
mesylate to prevent contrast agent-associated
nephrotoxicity. Journal of the American College of Cardiology 2004,
44:762-765.
58. Bagshaw S, Culleton B: Acetylcysteine for the prevention of
contrast nephropathy. JAMA 2003, 289:2795.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/2/38/prepub